Gain Therapeutics/$GANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gain Therapeutics
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Ticker
$GANX
Sector
Primary listing
Employees
21
Headquarters
Website
GANX Metrics
BasicAdvanced
$78m
-
-$0.61
0.11
-
Price and volume
Market cap
$78m
Beta
0.11
52-week high
$4.34
52-week low
$1.41
Average daily volume
656k
Financial strength
Current ratio
6.633
Quick ratio
6.455
Long term debt to equity
2.754
Total debt to equity
3.943
Profitability
EBITDA (TTM)
-18.686
Effective tax rate (TTM)
-4.46%
Management effectiveness
Return on assets (TTM)
-67.01%
Return on equity (TTM)
-155.66%
Valuation
Price to book
4.19
Price to tangible book (TTM)
4.22
Price to free cash flow (TTM)
-3.303
Free cash flow yield (TTM)
-30.28%
Free cash flow per share (TTM)
-0.56
Growth
Earnings per share change (TTM)
-31.45%
3-year earnings per share growth (CAGR)
-25.52%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gain Therapeutics stock?
Gain Therapeutics (GANX) has a market cap of $78M as of April 29, 2026.
What is the P/E ratio for Gain Therapeutics stock?
The price to earnings (P/E) ratio for Gain Therapeutics (GANX) stock is 0 as of April 29, 2026.
Does Gain Therapeutics stock pay dividends?
No, Gain Therapeutics (GANX) stock does not pay dividends to its shareholders as of April 29, 2026.
When is the next Gain Therapeutics dividend payment date?
Gain Therapeutics (GANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Gain Therapeutics?
Gain Therapeutics (GANX) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.